IceCure Medical Ltd. (ICCM): Kapitalisasi marang pendapatan

The revenue multiple level reflects the valuation dynamics of IceCure Medical Ltd (ICCM), where the value 0.60 represents the most recent figure. IceCure Medical Ltd (ICCM) has developed the innovative ProSense system, which destroys neoplasms using cold without the need for full surgery. Business development relies on the sale of profitable disposable probes, which optimizes costs. A team of leading biomedical experts ensures technological growth by focusing on patient needs.

The P/S multiple determines the market value of a business relative to its current revenue, allowing for an assessment of sales generation efficiency. By analyzing the P/S multiple trend, an investor can observe the dynamics of market expectations in real time. This ratio measures the premium the market is willing to pay per unit of revenue. For IceCure Medical Ltd (ICCM), high commercialization costs for cryoablation and a liquidity deficit make this indicator critical for assessing business viability.